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Abstract 
Inpatient mortality for hemodynamically stable patients with pulmonary embolism (PE) 
averages 5-10%. Tricuspid annular plane systolic excursion (TAPSE), a reliable and 
reproducible measure of right ventricular (RV) dysfunction has been shown to identify 
patients with worse prognosis in the cardiology literature, but prognostic utility of 
TAPSE using point-of-care echocardiogram (FOCUS) in the emergency department (ED) 
population is sparse. We propose that in a prospective cohort of patients with confirmed 
PE, those with TAPSE less than 15mm on FOCUS will have greater overall mortality and 
need for escalation of care than those with TAPSE greater than 17mm. We will enroll and 
follow patients diagnosed with acute PE, performing FOCUS with measurement of 
TAPSE within 6 hours of anticoagulation at academic emergency departments. We 
hypothesize TAPSE will independently predict outcomes in PE. Quantifiable and reliable 
measures that improve prognosis of ED patients may allow earlier identification of 
patients requiring escalation of care. 
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CHAPTER ONE: INTRODUCTION 
1.1 Background 
1.1.1 Epidemiology 
 Pulmonary embolism (PE) is the third leading cause of death from cardiovascular 
disease in the United States accounting for approximately 100,000 deaths per year1. The 
incidence rate for venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) in the United States is 1 to 2 per 10002,3. Though 
malignancy, surgery, and heart failure are all risk factors for VTE, the majority are 
idiopathic. Hospitalization is a significant risk factor for VTE, as approximately 25% are 
hospital acquired. However, 75% of VTE are community acquired making early 
diagnosis and prognostication in the emergency setting fundamental to effective 
treatment4. 
 There currently exists no registry for officially tracking the incidence of PE, but 
there have been several studies, which have demonstrated the burden this disease 
presents. In 1998 Silverstein et al.3 performed a 25 year population based study in 
Olmsted County, Minnesota and revealed and incidence of VTE to be 1.17 per 1,000 with 
a .69 per 1,000 incidence of PE. This trend has continued as Cushman et al.5 
demonstrated an incidence rate for first time VTE of 1.92 per 1,000 in a 2004 
retrospective cohort study. The study also noted a 28-day case-fatality rate of 11%. The 
1999 International Cooperative Pulmonary Embolism Registry examined 2454 patients 
with acute PE presenting at 52 hospitals in 7 countries revealing an overall all cause 
mortality rate of 17.4%, from which 45.1% were from PE6. Pulmonary embolism remains 
disease with high incidence and high mortality.  
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 The high incidence of first time VTE and its idiopathic etiology make emergency 
department diagnosis and assessment of prognosis very important to treatment. A 10-year 
cross-sectional study found an increase of PE diagnosis in the emergency department 
from 2001-2010. 86% of all PE patients were admitted with 75.1% of these patients were 
hemodynamically stable7. A retrospective cohort study of 61,249 PE admissions by 
Admon et al.8 identified a variation in ICU admission rates for PE from 2.9% to 79.9%. 
This evidence suggests inconsistent criteria for ICU admission in patients with PE. This 
also demonstrates not only an increasing incidence of PE diagnosed in the ED but also 
highlights the importance of the ED in managing and directing care of these patients. As 
the emergency department is where care is initiated, the importance of reliable risk 
stratification is essential to guide appropriate care.   
 
1.1.2 Pathophysiology  
 Pulmonary emboli are most commonly the result of deep vein thrombosis, when 
parts of the clot break off the thrombus, travel through the venous system, and become 
lodged in the pulmonary arteries. Here the clot grows, which ultimately obstructs blood 
flow to the pulmonary arteries of the lungs. The clot continues to grow and obstruct the 
pulmonary vasculature, leading to an increase in pulmonary vascular resistance (PVR). 
Significant rises in PVR leads to pulmonary hypertension, which increases right 
ventricular (RV) afterload. This increased RV afterload increases the tension within the 
ventricle, and severely increased tension leads to RV dilation, as well as increased end 
diastolic pressure in the right ventricle, RV compliance, and tricuspid regurgitation. 
Reduced efficacy of RV systolic function reduces LV filling, eventually reducing stroke 
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volume. As stroke volume is reduced significantly, cardiac output is reduced, leading to 
hypotension, systemic hypoperfusion and ultimately, hemodynamic collapse9,10.  
 Pulmonary emboli are categorized as small, submassive, or massive based upon 
clinical presentation. Massive PE as characterized by hemodynamic instability commonly 
defined as a systolic arterial blood pressure of < 90mm Hg or a drop of at least 40 mm Hg 
for at least 15 min or shock11,12.  Submassive PE patients are hemodynamically stable but 
exhibit right ventricular dysfunction (RVD) most commonly defined as RV hypokinesia, 
RV dilation, new onset pulmonary hypertension or paradoxical septal wall motion12.  
Small PE are pulmonary emboli with hemodynamic stability and no RV dysfunction10. At 
time of presentation up to 20% of patients with PE have abnormal blood pressure. 27-
55% normotensive patients have evidence of RV dysfunction, suggesting submassive PE 
can as such be ascribed to 21-44% of PE cases13-15. Identifying the severity of PE is 
important, as it influences treatment.  
  
1.1.3 Diagnosis  
 Acute pulmonary embolism (APE) can present in a variety of ways ranging from 
asymptomatic to shock and sudden death. Dyspnea, pleuritic chest pain, and cough are 
the most commonly associated symptoms 16,17. Because of these nondescript symptoms 
other clinical tools are utilized to assess the likelihood of PE, which are collected in 
Appendix A for reference.  Tests validated to assess the likelihood of PE include the wells 
score, modified wells score, modified Geneva score, and PE rule out criteria (PERC) 
scores in combination with a D-dimer18-23. The gold standard of diagnosis of Pulmonary 
embolism is the CT pulmonary angiogram (CTPA)24-26. In this specialized CT scan 
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intravenous contrast is injected to visualize the pulmonary arteries, which are then 
assessed for evidence of occlusion. When CTPA is unavailable or contraindicated, 
ventilation and perfusion (VQ) scans are sensitive and specific enough to diagnose PE27. 
Though often called a "great masquerader" due to its nonspecific symptoms, specific and 
sensitive pretest likelihood scores, and diagnostic tests such as CTPA and VQ scans make 
it possible to reliably diagnose the presence of PE. 
 
1.1.4 Treatment  
 Treatment of pulmonary embolism patients is currently based largely on their 
hemodynamic status upon diagnosis. Appendix B contains a sample treatment flow chart 
by Jaff et al12 consistent with the current literature on care of PE patients. Treatment for 
all noncontraindicated patients centers on anticoagulation, however further treatment 
depends on symptoms present.  
 Patients, who are hemodynamically unstable, require invasive therapy secondary 
to initiation of hemodynamic rescue with fluid resuscitation and intravenous 
vasopressors, as well as empiric anticoagulation28. Treatment with thrombolytic therapy 
has been established as a mainstay therapy for unstable patients with PE, with a large 
body of evidence advocating its efficacy29. Thrombolytic therapy carries a significant risk 
of intracranial hemorrhage and major bleed. Contraindications for thrombolysis include 
prior intracranial hemorrhage, recent stork, active bleeding, closed head trauma, 
suspected aortic dissection and known structural cerebral vascular lesion. In patients that 
thrombolytic therapy is contraindicated or failed, surgical embolectomy is indicated30. 
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 Patients who are hemodynamically stable with a small PE are often treated by 
anticoagulation alone. Though PE are often admitted for initiation of treatment, low risk 
patients with small pulmonary emboli can be managed as outpatients31-33. The typical 
length of anticoagulation is 3 months for an unprovoked VTE or 6-12 months if risk 
factors present34.  
 In patients with submassive PE the treatment plan becomes less clear. When 
treated with heparin alone, submassive PE can carry an in hospital mortality rate of up to 
12%13,26. The current standard of care for patients remains anticoagulation11,35. Typical 
anticoagulation regimens begin with unfractionated heparin therapy upon diagnosis, until 
patients are bridged to low molecular weight heparin, warfarin or direct oral 
anticoagulation11. Given the associated mortality with submassive PE, patients are often 
risk stratified using a Pulmonary Embolism Severity Index (PESI) score. The PESI score 
uses history of cancer, heart failure, chronic lung disease, heart rate, systolic blood 
pressure, respiratory rate, temperature, mental status and O2 saturation to risk stratify 
patients into levels 1-5 based on disease severity36,37.The PESI and simplified PESI have 
been validated as accurate predictors of adverse outcomes in PE patients38. This can be 
used to inform treatment options for patients, however many other patient specific 
prognostic factors also influence this decision.  
 Thrombolytic therapy is sometimes indicated in patients with submassive PE but 
it is currently utilized on a case-by-case basis. The literature regarding the use of 
thrombolysis in normotensive patients is contentious but tends to advocate against the use 
of thrombolysis in submassive PE11,39,40. Though not always statistically significant, 
studies such as the one performed by Meyer et al.41 show clinically significant benefit to 
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treating submassive PE, patients with tenectepase over anticoagulation alone, with a 
statistically significant reduction in hemodynamic decompensation. This was however 
coupled with a 2.0% increase in hemorrhagic stroke and 6.3% increase in major extra 
cranial hemorrhage. This study highlights the current paradox in management of 
submassive PE. Thrombolytic management of the patient's risk of death and 
hemodynamic decompensation puts the patient at increased risk for bleed42. One 
observational study noted an improvement of RV function in patients with reduced 
TAPSE, who received thrombolytic therapy, however it was not powered to assess 
mortality benefit43. A more refined quantifiable assessment of hemodynamic risk, such as 
TAPSE, would allow a clinician to better navigate the risk of bleed and hemodynamic 
decompensation when managing normotensive PE patients.  
 
1.1.5 Prognosis  
 Though CTPA and VQ scans provide clear diagnosis for PE, predicting the 
clinical course of patients with pulmonary emboli is far more nuanced. Evidence of 
hemodynamic instability and shock have been clearly associated with increased 
mortality, which demonstrates a need for consideration invasive treatment and escalation 
of care11,35. In normotensive patients with PE, there remains a risk of hemodynamic 
decompensation and death, but currently available prognostic tools and tests have not 
created a clear guidance for treatment. The mortality rate of submassive PE and 
subjective care guidelines currently available necessitate better prognostic tools, which 
have not yet been definitively described in the literature.  
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Shock  
 Hemodynamically unstable patients with pulmonary embolism, as defined in 
pathophysiology, have been associated with the greatest incidence of mortality. It is the 
most common cause of death from pulmonary embolism. When present it has been 
associated with a 25-30% mortality rate12,44,45. The literature has demonstrated PE 
patients presenting with shock as having an in hospital mortality rate of 32%14.  
 
Right Ventricular Dysfunction  
 Right ventricular dysfunction has been associated with adverse outcomes in 
patients with PE11,35,46,47. RVD varies in definition, but in much of the existing literature 
it is described as RV dilation with an RV/LV end-diastolic diameter >30mm, an RV end 
diastolic diameter > 1, and paradoxical septal systolic motion11,35. A meta-analysis of 
3283 patients comparing short term mortality of patients hemodynamically stable acute 
PE patients with right ventricular dysfunction with those with normal RV function. They 
found that PE patients with RVD as assessed by echocardiogram had an odds ratio of 
2.29 compared to those with normal RV function48. A 2011 meta-analysis 3 month 
mortality of 1249 patients with acute PE found an odds ratio of 2.36 of increased 
mortality in patients with RVD as assessed by echocardiogram49. Through meta-analysis 
and cohort studies a clear association between right ventricular dysfunction on 
echocardiogram and mortality in hemodynamically stable patients with acute PE is 
evident. 
 The association between RVD and mortality has not had a large impact on 
treatment however, as benefit of thrombolytic therapy in hemodynamically stable patients 
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with RVD has not shown significant benefit over anticoagulation alone and carries a risk 
of intracranial hemorrhage and major bleed39-41. This was evidenced by Konstantinides et 
al.50 in a 2002 randomized control trial, which showed no difference in mortality in 
submassive PE patients receiving thrombolytic therapy compared to those receiving 
heparin alone. Meyer et al.41 demonstrated an odds ratio of 0.44 in patients receiving 
thrombolysis developing endpoints of mortality and hemodynamic decompensation 
compared to those receiving heparin alone, but this was coupled with an increase risk of 
major bleed. Though evidence of poor RV function has been associated with increased 
mortality, it has not had a large impact on care. A more reliable measure of RVD, such as 
TAPSE, may help to better guide therapy.  
 
1.1.6 Tricuspid Annular Plane Systolic Excursion  
 One measurement of right ventricular dysfunction is tricuspid annular plane 
systolic excursion (TAPSE). The right ventricle's muscle fibers are oriented in a 
longitudinal direction resulting in a longitudinal contraction of the right ventricle during 
systole. This physiology can be measured by transthoracic echocardiogram (echo) in a 4-
chamber window as the base moves towards the apex of the heart with contraction. The 
m mode cursor is used along the tricuspid annulus measuring the maximum distance 
traveled by the tricuspid annulus during systole51,52. There remains contention in 
physiological normal baseline of TAPSE but a TAPSE of greater than 17 mm is often the 
accepted value52,53.  
 TAPSE has been shown to be an accurate predictor of right heart function52,54,55. 
Kaul et al. first described this correlation in 1984, demonstrating TAPSE's association 
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with right ventricular ejection fraction (RVEF) as confirmed by radio nucleotide 
angiography51. Ueti et al.56 built upon these findings as in a cross sectional study of 30 
patients, 10 with normal RVEF and 20 with reduced RVEF due to known pathologies of 
pulmonary hypertension, dilated cardiomyopathy, liver cirrhosis, systemic hypertension 
or congenital defect. They found TAPSE was statistically significantly reduced in 
patients with reduced RVEF. Recent studies have shown low TAPSE to predict mortality 
in pulmonary hypertension57,58, ischemic cardiomyopathy59,60, chronic obstructive 
pulmonary disease (COPD)61, and myocardial infarction62. The cardiology literature 
demonstrates prognostic utility in utilizing TAPSE to risk stratify PE63-65. These studies 
however often fail to control for other confounders effecting TAPSE and lack uniform 
definition of reduced TAPSE.  
 Recent studies have demonstrated an association between a reduced TAPSE and 
mortality in patients with APE. These studies have largely been limited to the cardiology 
literature but have shown TAPSE of 14mm to 17mm to be associated with greater 
mortality in normotensive patients with pulmonary embolism63,64. TAPSE measurement 
is reliable and reproducible when performed by clinicians trained in ultrasound66. The 
diagnostic value of TAPSE in the ED remains contentious, but there is room for studies 
associating reduced TAPSE measured in the emergency department prognosis of 
normotensive patients presenting with acute PE based on existing literature. The existing 
literature regarding the prognostic utility of TAPSE in pulmonary embolism will be 
explored further in Chapter 2. 
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1.2 Statement of the Problem 
 The mortality rate of normotensive patients with PE is 5-10%, despite sensitive 
and specific diagnostic tools and effective treatments11. Admission to the intensive care 
unit in this population is often inconsistent with currently available prognostic tools8. In 
this patient population, anticoagulation remains the standard of care, despite this 
continued high inpatient mortality rate. Escalation of care beyond anticoagulation, such 
as thrombolytic therapy remains contentious treatment with mixed results in 
normotensive patient presenting with APE, and is currently considered on a case by case 
basis among hemodynamically stable patients presenting with acute PE and RVD11,35. 
Mixed results in thrombolytic therapy in patients with submassive PE, as well as a high 
mortality rate on anticoagulation alone necessitate the need for more reliable prognostic 
guidelines informing the need for escalation of care.  
 Tricuspid annular plane excursion can be routinely and reliably measured in 
emergency departments when evaluating PE patients. Low TAPSE has been associated 
with poor clinical outcomes in several cohort studies63,64,67. Clinical outcomes of 
hemodynamic decompensation and mortality have been associated with TAPSE values of 
14mm to 20mm63,64,67. However, there remains no standard value of TAPSE associated 
with presentation in the emergency department that can serve as a guide the need for 
escalation of care. A clear threshold value of TAPSE established with greatest association 
with poor clinical outcomes could help to better guide therapy of hemodynamically stable 
patients with acute PE in the ED.   
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1.3 Goals and Objectives 
 The goal of this study is to establish a threshold minimum value of tricuspid 
annular plane excursion measured with point-of-care echocardiogram in the ED, at which 
patients with submassive pulmonary embolism are most associated with requiring 
escalation of care beyond heparin alone or increased mortality.  In order to do so, we will 
determine if a TAPSE value below 15mm is associated with hemodynamic 
decompensation and mortality in normotensive patients presenting in the emergency 
department with APE, as opposed to a TAPSE value greater than 17mm over the course 
of a hospital admission of up to 14 days. TAPSE will be obtained by point-of-care 
focused cardiac ultrasound (FOCUS) at the bedside performed, measured and read by ED 
physicians trained in FOCUS use. We will also compare hospital length of stay between 
patients with a TAPSE of less than 15mm to those with a TAPSE greater than 17mm. We 
will also establish if TAPSE is a more reliable prognostic indicator than RV/LV for 




Pulmonary embolism (PE) patients with a tricuspid annular plane systolic excursion 
(TAPSE) less than 15mm measured by point-of-care echocardiogram will be 
independently associated with an increased higher need for escalation of care beyond 
heparin alone and higher mortality than PE patients with TAPSE greater than 17mm. 
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Secondary: 
Pulmonary embolism patients with a TAPSE less than 15mm measured by point-of-care 
echocardiogram will be independently associated an increased hospital length of stay 
than PE patients with TAPSE greater than 17mm. 
 
Pulmonary embolism patients with a TAPSE less than 15mm will have a statistically 
significant increased need for escalation of care beyond heparin alone and higher 
mortality than patients with an RV/LV ratio of greater than 1.' 
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CHAPTER TWO: REVIEW OF LITERATURE 
 
2.1 Introduction   
 In this critical review of the literature, the existing evidence for and against the 
use of point-of-care measured tricuspid annular plane systolic excursion in prognosis of 
normotensive patients with acute pulmonary embolism will be examined, followed by 
analysis of the accuracy, reproducibility and utility of emergency department point-of-
care echocardiography in the management of patients with PE, followed by a review of 
relevant literature regarding possible confounding variables. In order to perform this 
literature review, an extensive search was performed between July 2017 and May 2018 
using the Scopus, Ovid MEDLINE, and PubMed databases. The following search terms 
were utilized in combination across each database: pulmonary embolism, submassive 
pulmonary embolism, right ventricle dysfunction, tricuspid annular plane systolic 
excursion, point-of-care ultrasound, bedside ultrasound, echocardiogram, emergency 
department, prognosis, hemodynamic decompensation, escalation of care, and mortality.  
No limit was placed on year of publication. The search was limited to English language 
sources and utilized articles included systematic reviews, meta-analysis, cohort studies, 
randomized clinical trials and case-control studies. Sources cited by selected articles were 
also reviewed to find additional sources.  
 
2.2 Review of Empirical Studies About the Relationship Being Studied 
2.2.1 Evidence demonstrating association of RV dysfunction and PE prognosis 
 A strong body of evidence exists associating increased mortality and need for 
escalation of care in PE with right ventricular dysfunction. The most consistent definition 
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of RVD used in the literature is an RV end diastolic value > 30mm, RV/LV ratio of  >1, 
and paradoxical sepal wall motion, pulmonary hypertension > 30 mmHg, and a tricuspid 
regurgitant velocity >2.8m/s1. Studies vary considerably in their definitions of RVD and 
what measurements are included in analysis. Though the literature demonstrates an 
association between right ventricular dysfunction and mortality, there remains little 
consensus on the most accurate marker of RV dysfunction.  
 Ribeiro et al. 2 observed an association between RV systolic dysfunction, as 
identified on echocardiogram in the emergency department within 1 day of PE diagnosis 
and death in a prospective cohort of 126 patients. In this cohort 10 of the 70 patients with 
RVD experienced in hospital mortality with a p = 0.002.  This study identified right 
ventricle dysfunction as qualitatively evaluated moderate and severe RV wall 
hypokinesis. This 1997 prospective cohort was one of the first papers to identify the 
relationship between RV dysfunction and PE mortality.  
 There were several limitations of this study. There is no identification of 
hemodynamic status of the patients in the study, in which 37 patients in this study 
received thrombolytic therapy. There is a well-defined association between hemodynamic 
instability and mortality in the literature3,4.  This makes results less generalizable to risk 
stratification, as unstable patients will have increased mortality rate.  
 A 2000 prospective study by Grifoni et al.5 of 162 normotensive patients 
presenting with acute PE found an incidence of RV dysfunction of 40%. 6 of the 65 
patients with RV strain and PE developed shock during admission and 3 died. This study 
defined RVD as RV dilation, paradox septal wall motion, and doppler evidence of 
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pulmonary hypertension. In this study none of the patients without RVD died, conferring 
a sensitivity and negative predictive value of PE related death of 100%.  
 There remain several limitations to the study. Statistical analysis was not 
completed on RVD and mortality in this study making the association only clinically 
significant. Patients who decompensated in this study had statistically significant lower 
blood pressures and age on presentation, as average blood pressures were 130 + 17 in the 
stable patients, while patients with worsening clinical course and death had presenting 
blood pressures of 105 + 29. 15% of stable patients were over 80 years old, while 67% of 
decompensating patients were. Advanced age and hypotension have been associated with 
worse outcomes in PE, making these differences substantial demographic differences 
when utilizing this study's findings4.  
 Zhu et al.6 demonstrated an odds ratio of 5.23 in patients with RVD developing 
clinical endpoints of 14-day mortality, need for vasoactive agents, endotracheal 
intubation, or cardiopulmonary resuscitation in a prospective study of 520 normotensive 
patients diagnosed with PE. RVD was assessed on echocardiogram and defined as 
RVED/LVED >0.6, RV hypokinesis, loss of inspiratory collapse of IVC, or tricuspid 
regurgitant velocity of >2.8 m/s. Though RVD was associated with increased adverse 
events in this study, only RVED/LVED of >0.6 and RV hypokinesis reached statistical 
significance as independent predictors of mortality with odds ratios of 4.19 and 1.59 
respectively.  
 This prospective study had several limitations. The definition of right ventricular 
dysfunction was very broad, which may have increased the incidence of RVD in this 
group. The study documented an RVD incidence of 47.7% in the study population, which 
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is higher other studies. Patients presenting in the RVD group were also more 
symptomatic on presentation with statistically significant differences in dyspnea, 
syncope, hypertension, and concomitant DVT than those with no RVD. The more 
advanced symptomology may have contributed to a greater mortality rate in the RVD 
group of 26.6% compared to 9.9% in the group without RVD6. The study also failed to 
outline the therapy given for both groups as mortality in this study was higher than 
elsewhere in the literature where the mortality rate for PE 0.4-0.9 % in patients with PE 
but no RV dysfunction7.  
 A 2014 meta-analysis by Cho et al.8 of 3283 patients comparing 30-day mortality 
of patients, hemodynamically stable PE patients with RVD as assessed by 
echocardiogram had a 2.29 increase in mortality than those with preserved right ventricle 
function. This corroborated the findings of Coutance et al.9 in a 2011 meta-analysis 
analyzing the 3-month mortality of 593 hemodynamically stable PE patients. 
Investigators demonstrated a 2.36 increase in mortality among patients with RVD 
compared to those with normal function. This study did not include TAPSE in its analysis 
but did use the definition of RVD as RVED/LVED of >0.9, which is a higher threshold 
than other studies, which often use an RVED/LVED of >1.0. This more advanced 
definition of RVD may have included patients in the normal RV function group, who 
may be classified as having RVD in other studies.  
 The meta-analysis by Cho et al. 8 only used one database, PubMed, in its search 
limiting the power of its results. It did not include studies with clinical endpoints outside 
of its established 30-day mortality limiting he including of several studies with endpoints 
of 14-day, 40-day or 3-month mortality. The meta-analysis by Coutance et al.9 included 
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evidence of right ventricular dysfunction from CT scan. This is creates some 
inconsistency with measurement as most literature utilizes echocardiogram to assess 
RVD and there exists some variability in measurement of RD strain between CT and 
echo10. Both meta-analysis were limited by an inconsistent definition of RVD in the 
literature, such as the value of RV/LV ranging from 0.8-1.0 in different studies.  
 Not all the literature supports the association between RVD and increased 
mortality however. In a 2017 study of 134 patients Chaudhary et al.11 found no difference 
in 30-day mortality between normotensive patients with RVD compared to those with 
preserved RV function. In this study 6 of 77 patients with RVD died, while 3 of 57 
patients without RVD died. The mortality rate for patients with RVD in this study way 
7.8%, which is consistent with other studies, however the mortality rate among patients 
with normal RV function was 5.3%, which is higher than other studies within the 
literature3.  
 The patient population in this study had a high prevalence of malignancy, at 
approximately 31% and 50% in both groups respectively. Malignancy has been 
independently associated with mortality in patients with APE4. This study was further 
limited by the high prevalence of RVD in the study population. 57% percent of patients 
enrolled has RVD, which is a larger prevalence than cited in most other studies1. The 
greater prevalence of patients with RVD and higher mortality rate in the normal RV 
function group may represent enrollment of more severe patients in the study.    
 Overall, right ventricular dysfunction has been identified in existing literature as 
having a demonstrated association with PE related mortality and need for escalation of 
care. This association has been limited by an inconsistent definition of RVD, as 
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measurement thresholds and qualities of RVD differ between studies. Many studies in the 
existing body of literature do not include a TAPSE measurement in their designs. A 
review of existing literature highlights the need for a reliable and easily obtained 
measurement of RV function for consistent prognostic value in hemodynamically stable 
patients with acute PE. 
  
2.2.2 TAPSE as a marker of RV dysfunction  
 Although right ventricular dysfunction has been associated with poor prognosis in 
normotensive pulmonary embolism patients, the definition of RVD can be met with 
several criteria. Tricuspid annular plane systolic excursion has been demonstrated in the 
literature to be a useful, reliable, and reproducible marker of right ventricular function in 
normotensive PE patients. In several studies reduced TAPSE has demonstrated a greater 
association with mortality than other markers of RVD.  
 In the 2014 prospective cohort study Lobo et al.12 enrolled 782 normotensive 
patients with APE comparing those with TAPSE > 1.6 cm to those with a TAPSE of ≤ 
1.6 cm. Those with a TAPSE of ≤ 1.6 cm were found to have statistically significant 
increased systolic pulmonary artery pressure, RV end diastolic diameter, RV/LV end 
diastolic ratio and increased prevalence of RV hypokinesia. Mortality in the group with a 
TAPSE of ≤ 1.6 cm was significantly higher, as the hazard ratio (HR) was 2.3 from any 
cause and 4.4 from PE related death. 146 of the 782 patients enrolled in the study had a 
TAPSE of ≤ 1.6 cm representing a prevalence of 18.6% in the study population. 
 This study demonstrates a significant association between TAPSE ≤1.6 mm and 
mortality, but it has several limitations. 22 of 146 (16%) of patients with RVD had a 
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history of COPD and 14 (10%) patients had a history of congestive heart failure (CHF). 
CHF and COPD have been associated with decreased TAPSE values13-15. Reduced 
TAPSE in these pathologies has also demonstrated association with poor prognosis, 
possibly confounding data14-16. This study also utilized data from transthoracic 
echocardiogram taken within 24 hours of diagnosis. This is inconsistent with our study, 
as we will perform point-of-care echocardiogram in the ED upon diagnosis. Though the 
findings of the Lobo et al.12 study demonstrate a correlation of TAPSE of ≤ 1.6 cm and 
mortality, its methodology does not demonstrate how TAPSE can be utilized in the ED 
for prognostication.  
 Pruszycyk et al.17 analyzed the echocardiographic parameters associated with 
right ventricular dysfunction in a 2014 study of 411 hemodynamically stable patients 
presenting with APE to the emergency department with clinical endpoints of 30-day PE 
related mortality and/or thrombolysis. 241 of the 411 patients enrolled were classified as 
having submassive PE. 21 of 411 patients reached clinical endpoints and 19 of these 
patients were from the submassive PE group. The average TAPSE in the clinical endpoint 
group was 12mm with a range of 6-20mm, while TAPSE in the remaining patients 
averaged 21mm with a range of 6-34mm, with a p value of <0.0001. In this study TAPSE 
≤ 15mm showed a hazard ratio of 27.9, and a TAPSE of  < 16mm showed an HR of 
14.48. This study also found TAPSE ≤ 15mm to have a higher positive predictive value 
of PE related mortality and thrombolysis at 22.5%, than an RV/LV ratio of >1 at 13.1%. 
 This study demonstrates an association between a TAPSE of ≤15mm and PE 
related mortality and/or thrombolytic therapy in hemodynamically stable patients with 
APE. Though statistically significant associations with the clinical endpoints were also 
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identified with several echocardiographic parameters including RV/LV ratio of >1, HR of 
7.71, McConnell's sign, HR of 3.6, these associations have frequently been identified in 
the literature1,7. TAPSE of ≤ 15mm remained the measurement of RVD with the strongest 
association with the clinical endpoints with an HR of 27.9.   
 This study was performed on patients admitted from the ED and the study 
population included 142 of 411 patients with COPD, CHF, or neoplasm, including 9 of 
the 21 patients reaching clinical endpoint17. This population includes patients with 
conditions known to have associations with reduced TAPSE and increased mortality with 
TAPSE ≤16 mm14. Echocardiography was performed immediately on admission in 193 
patients, within 24 hours in 159 patients, and between 24 and 72 hours after admission in 
59 patients, showing some inconsistency in data collection. Though all echocardiograms 
were read by a standardized protocol, the echo may have been taken after therapy was 
initiated in these patients possibly confounding results.  
  In 2016 Paczynska et al.18 enrolled a cohort of 76 hemodynamically stable 
patients presenting with APE with echo obtained as soon as possible upon admission. 8 
out of 76 patients had PE related mortality within 30 days of diagnosis. The average 
TAPSE value for the mortality group was 12.3 ± 3.6, while in the remaining patients 
TAPSE was 20.3 ± 5.2. TAPSE was the only value of RVD to have statistically 
significant mortality prediction, with an HR of 0.73, while RV/LV ration >1 failed to 
reach statistically significant association. The TAPSE ≤ 15 mm showed a PPV of 
43.75% for PE related mortality and negative predictive value of 98.3%. This study 
demonstrates TASPE as a powerful prognostic factor for submassive PE.  
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 This study has several limitations. The sample size of 76 patients is small. 
Paczynska et al.18 also enrolled patients with comorbidities in their study. Patients with 
COPD, CHF, or neoplasm made up 30% of the study population and 50% of the 
mortality group, though not statistically significant, this could possibly influence TAPSE 
measured in this population. Mortality and survival groups had a statistically significant 
differences in heart rate, 110 compared to 87 bpm, and age, averaging 82 compared 6618. 
Age and presenting heart rate may have been contributory as both have been associate 
with poor prognosis for PE previously1,3.  This study lacks a specific protocol for when to 
obtain echocardiography, other than obtaining it as soon as possible. Without a structured 
time of obtaining ultrasound, external validity is diminished as the value may have been 
affected by therapy up until that point.   
 Reduced TAPSE was associated with hemodynamic instability and shock in the 
2017 study by Rabie Samra et al.19. The prospective cohort study of 50 patients with APE 
placed patients into group I, hemodynamic instability, group II, hemodynamic stability 
with RVD and group III, hemodynamic stability with normal RV function. Group I had 
an average TAPSE of 13.8 + 2.02, while group II and III had respective TAPSE 
measurements of 15.37+ 1.7 and 19.67 + 1.66. The difference in TAPSE among groups 
demonstrated a statistically significant, p= 0.0047, association between reduction in 
TAPSE with pulmonary embolism severity. Reduced TAPSE correlated with day 1 
mortality, as 6 of the 13 patients with TAPSE < 14 mm died in this study. 6 of the 16 
patients in this study with a high risk PESI score, PESI >124, died, demonstrating a 
higher accuracy of TAPSE in prediction of acute PE mortality. Linear regression analysis 
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of PESI and TAPSE showed a very strong negative correlation, demonstrating a 
correlation between high PESI score and objectively measured reduced TAPSE.  
 The study by Rabie Samra et al.19 has several limitations. It was a single center 
study with a small patient population of only 50 patients in Saudi Arabia limiting its 
generalizability to a larger American population. The inclusion of hemodynamically 
unstable patients, though demonstrating an association between TAPSE and disease 
severity, limits the study's relevance in risk stratifying hemodynamically stable APE 
patients. Statistical analysis was not performed on the hemodynamically stable with RVD 
population alone, though the group did exhibit a 13% mortality rate and 4 of the 15 
patients required thrombolytic therapy. The TAPSE of < 14mm used in this study is also 
lower than cited in many other studies, which may result in a greater association than 
would be present at a higher TAPSE threshold.  
 Zanobetti et al.20 investigated how echocardiographic measurements could predict 
RVD, and how these measurements were affected by PE treatment. This study showed 
that though TAPSE is reduced in APE, RV function recovers with anticoagulation or 
thrombolytic therapy. In the population of 120 APE patients, the mean TAPSE on 
presentation was 15 + 7mm. When remeasured after 7 days of therapy, TAPSE improved 
to 20 + 6mm and improved to 22 + 6mm after 1 month of treatment. Sub-analysis 
revealed that in patients with a TAPSE <15 mm and pulmonary hypertension, only 
patients receiving thrombolytic therapy had improved RV function, while TAPSE 
remained reduced in patients receiving heparin therapy alone. This study thus 
demonstrates that patients with TAPSE < 15mm and pulmonary hypertension may 
benefit from thrombolytic therapy. Investigators found no statistical correlation between 
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TAPSE and 7 day mortality within the study. This prospective cohort study illustrates 
only how RV function may be improved with therapy and treatment. 
 In a 2012 prospective cohort study of 50 patients with APE, Park et al. 21 found 
TAPSE to be a reliable marker of RV systolic dysfunction. This study identified 39 
patients with RVD as assessed by right ventricular fractional area change. Investigators 
identified a TAPSE of < 17.5mm as an ideal cut off for identifying RVD with a 
sensitivity of 87% and specificity 91%. In the study 2 patients died of PE related events, 
which demonstrated no statistical correlation with TAPSE < 17.5mm on multivariate 
analysis.  
 This was a small study of only 50 patients. It used stored patient images for 
analysis, which may have affected the quality of measurements taken. RV systolic 
function was assessed by right ventricular fractional area change, which may not have 
been the most accurate control. a TAPSE of 17mm has been identified in the literature as 
being within physiological normal range22,23, making TAPSE <17.5mm a high definition 
of RVD. This high TAPSE may have played a part in there being no statistically 
significant relationship with mortality.  
 Much of the existing literature demonstrates consistent correlation between 
reduced TAPSE and mortality or hemodynamic decompensation, though some smaller 
studies have not found a significant association. There exists some inconsistency in 
definition of reduced TAPSE, as it has been described from  > 14mm to  > 17.5mm in 
different studies. The majority of the literature come from a cardiology perspective, but 
most studies attempt to take TAPSE measurements as close to presentation as possible, 
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usually while the patient is in the ED. Further studies outlining the prognostic utility of 
TAPSE as patients they are diagnosed in the ED would strengthen the existing literature. 
 
2.2.3 Interobserver reliability of TAPSE 
 TAPSE has been utilized to assess right heart function since it was first identified 
by Kaul et al. in 198424. It is routinely measured in echocardiography and can be obtained 
through point-of-care ultrasound in the emergency department. There have been several 
studies performed demonstrating the interobserver reliability of point-of-care 
measurement of TAPSE is consistent and accurate.  
 Kopecna et al. compared interpretations of RV enlargement, RV/LV ratio, RV 
free wall hypokinesia and TAPSE on echocardiogram by central and local cardiologists 
in 75 patients presenting with APE. Mean TAPSE measured by both central and local 
cardiologists was 2.1 ± 0.4 cm. The intraclass observation of TAPSE was deemed very 
good with a kappa value of 0.85. When RV dysfunction is defined as a TAPSE of ≤ 1.6 
cm the two observers agreed whether RV dysfunction is present or not with a weighted 
kappa of 0.86. This demonstrates consistent measurements of TAPSE among 
cardiologists. The interobserver agreement for RV dilation, RV/LV ratio, and RV 
hypokinesia was markedly reduced compare to TAPSE with kappa values of 0.45, 0.65 
and 0.70 respectively25. This study found TAPSE to have the greatest observer reliability 
among echo measured values of RVD.  
 This study was limited by the fact that only 8 patients in the study had TAPSE ≤ 
1.6, meaning that, despite the clear consensus in interpretation, the sample size for the 
dysfunction group was small. The study demonstrates that among cardiologists TAPSE is 
 30  
the least user dependent and most reproducible indication of RVD on echocardiogram in 
normotensive patients with PE. This study also highlights values of RV/LV ratio and RV 
dilation have lower interobserver agreement, leaving more room for error in 
interpretation when using the test for guiding treatment. This is a study of cardiologists, 
so the generalizability of the study for use in the ED is limited.  
 Weekes et al. demonstrated interobserver consistency when assessing RVD in a 
2016 study which compared the interpretation of 9 packets of echocardiographic images 
taken of normotensive patients presenting with acute PE in the emergency department by 
2 emergency physicians and 2 cardiologists. In this study TAPSE of <10mm with RV 
free wall hypokinesia was included with RV/LV ratio >1.0 and interventricular septum 
flattening in the definition of RV dysfunction. In this study there was 74.2% agreement 
on the presence of RV dysfunction with a kappa value of 0.6926. The findings were in line 
with the findings of Kopecna et al., in which interobserver agreement of RV/LV ratio 
>1.0 was 0.6525.  
 This study has several limitations. It does not look at TAPSE independently 
limiting the applicability of the study in validating the use of TAPSE. Though in this 
study TAPSE was not looked at independently its inclusion in the definition of RV 
dysfunction, demonstrates continued interobserver agreement when present. The 
definition of RVD in this study uses a TAPSE of < 10mm, which is lower than most 
definitions in the literature and may be easier to assess for observers to assess, but also 
less likely in a normotensive patient given its severity.  
 The use of point-of-care focused cardiac ultrasound by emergency department 
physicians to assess TAPSE was evaluated in the 2017 prospective cohort study by Daley 
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et al.. The study enrolled 150 patients, 32 of whom were PE positive, who received 
FOCUS. When emergency physicians performed FOCUS with an abnormal TAPSE 
cutoff of <1.7 cm the kappa value was 0.94, demonstrating an excellent ability of 
emergency physicians to accurately identify abnormal TAPSE with FOCUS. The study 
used intraclass correlation coefficient (ICC) to demonstrate interpreter reliability for 
TAPSE.  Investigators found an ICC of 0.87, when comparing measurement of TAPSE 
by 2 emergency physicians in 30 of the study's subjects27.  This finding demonstrates that 
FOCUS performed by trained emergency physicians identifies consistent and reliable 
measurements of TAPSE.  
 This study was designed to demonstrate FOCUS measured TAPSE for diagnosing 
PE rather than prognosticating it, however the interobserver reproducibility and accuracy 
demonstrated can be applied to the use of this measurement for prognosis as well. This 
study utilized an abnormal TAPSE cutoff of 1.7 cm, while our study will use an abnormal 
TAPSE cutoff of 1.5 cm, which may affect the application of this study, as it was not 
designed to use this value. Daley et al. used emergency physicians with extensive training 
and experience in point-of-care ultrasound, which may not be consistent with the 
capabilities of all emergency physicians, reducing the study's generalizability27.  
 The existing literature on the reliability of TAPSE remains sparse with 3 studies 
assessing interobserver reliability in measuring TAPSE. TAPSE had greater reliability 
and reproducibility than RV/LV ratio, RV dilation, and RV hypokinesis in the cardiology 
literature, favoring its use in guiding treatment for PE. Daley et al.27 demonstrated 
excellent reliability in using FOCUS to measure TAPSE in the ED. The existing literature 
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shows echocardiographic measurement of TAPSE to be a reliable measurement of right 
ventricular function.  
 
2.2.4 Point-of-care cardiac ultrasound use in the emergency department  
 The literature demonstrating use of TAPSE in the emergency department to guide 
treatment of pulmonary embolism remains sparse. The use of point-of-care or bedside 
cardiac ultrasound in diagnosis and prognosis of pulmonary embolism in the ED has been 
addressed in several studies however. FOCUS is a routinely used and useful tool in the 
ED with its use recommended by the American Society of Echocardiography and 
American College of Emergency Physicians28. The majority of the studies look at 
ultrasound performed and read by experienced and specifically trained emergency 
physicians. These studies have shown considerable variation in interobserver agreement, 
but also demonstrate benefit to their use in PE prognosis.   
 Taylor et al. 29 analyzed the focused limited echo examinations of 411 patients 
presenting to the ED with suspected cardiac etiology and received consultation 
echocardiogram within 72 hours comparing findings of the right ventricular strain on 
echocardiogram in a 2014 retrospective cohort study. 69 providers performed focused 
limited echocardiograms in the study over a 12-month period. RV strain was noted in 
6.2% of patients on limited echo, while it was observed in 18% of patients on 
consultative echo. The kappa value for agreement of RV dilation was 0.44. The 
agreement increased with training as fellowship-trained providers had a kappa value of 
0.55.  
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 Though agreement was not ideal in this study, the presence of RV dilation on 
limited echo was quite specific at 0.98, while it was not sensitive at 0.26. This 
demonstrates the feasibility of using limited echo to identify RV dysfunction in helping 
to prognosticate PE patients. While this study was not limited to patients with confirmed 
PE, the interobserver agreement and specificity of limited echo demonstrates its 
usefulness.  TAPSE was not included in this study, but it is capable of being measured 
with limited ultrasound and could used to more clearly prognosticate echo with limited 
echo.  
 A 2013 retrospective chart review was performed on 161 patients diagnosed with 
PE and who received a emergency physician performed point-of-care focused cardiac 
ultrasound (FOCUS) in order to identify its prognostic value in predicting in hospital 
adverse events in PE patients. In the review right ventricular strain was defined as 
RV/LV ratio of >1, RV hypokinesia or a McConnell's sign, while adverse outcome was 
defined as shock, respiratory failure requiring intubation, death or recurrent VTE. 25 of 
the 161 patients enrolled experienced adverse events. RV strain as assessed by FOCUS 
had statistically significant predicative value with an odds ratio of 9.2.30  
 This study did not include TAPSE in its definition of RV strain this study 
demonstrates the utility of FOCUS use in emergency departments in predicting adverse 
outcomes in PE patients. As TAPSE has been found in other studies to predict mortality 
better than RV/LV ratio, which was the most common finding of RV strain in this study, 
utilization of TAPSE in point of care ultrasound could benefit prognostication of PE. The 
study was limited by possible selection bias, as it only enrolled patients receiving FOCUS 
in the ED, which may select for more advanced patients. This study was performed by 
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ultrasound experienced emergency physicians, which reduces its generalizability to a 
broader population of providers.  
 Dresden et al. 31 performed a prospective observational study of 146 patients with 
suspected to pulmonary embolism to assess bedside echocardiography for diagnosis of 
PE. Researchers found an observed agreement of 100% between 4 emergency medicine 
physician investigators and blinded cardiologists in assessing right ventricular 
dysfunction measured by one of the investigators on bedside ultrasound. Though this 
study was not designed to demonstrate bedside echocardiography in predicting mortality, 
it demonstrates interobserver agreement on the measurement of right ventricular strain 
with bedside echo.  
 FOCUS and bedside echo are currently utilized in emergency departments to 
assess RV dysfunction in patients with pulmonary embolism. There remains some 
limitation of interobserver reliability in assessing RVD, but the FOCUS has shown 
prognostic benefit when used in the ED. TAPSE has been shown to have a greater 
amount of interobserver agreement in the published literature with kappa measurements 
of 0.85 25 and 0.9427 demonstrating greater  reliability than the 0.44 assessed by Taylor et 
al.29. TAPSE may provide more reliable measurements than are already being utilized in 
the ED for evaluation of PE. The findings of our study may help point-of-care ultrasound 
to be more accurately, reliably, and effectively utilized in guiding therapy for APE 
patients. 
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2.3 Review of Studies to Identify Possible Confounding Variables 
2.3.1 Pathologies affecting TAPSE  
 Our proposed study has identified a tricuspid annular plane systolic excursion of 
< 15mm as a prognostic indicator for need for escalation of care beyond heparin alone 
and mortality in patients with submassive pulmonary embolism. Pulmonary embolism is 
not the only pathology, which can reduce TAPSE however. There have been several 
studies, which demonstrate COPD and CHF can reduce TAPSE. This would create an 
unclear clinical picture, as PE might not be the cause of reduced TAPSE in these cases.  
 Ghio et al.32 studied TAPSE in 140 patients with chronic congested heart failure. 
They identified a TAPSE of < 14mm was associated with increased death from CHF. 
TAPSE < 14mm had a hazard ratio of 2.58 and was a strong predictor of mortality, 
especially when coupled with NYHA class II or IV heart failure. This study also 
demonstrated excellent intraobserver and interobserver correlation with r-values of 0.94 
and 0.93 respectively. This study demonstrates correlation of CHF and reduced TAPSE.  
 Kjaergaard et al.14 found in a prospective cohort of 817 patients with CHF a 
hazard ratio of 0.74 for every doubling of TAPSE. The most mortality was identified in 
patients with a TAPSE <14mm. In this study COPD was also found to increase mortality 
with a hazard ratio of 2.39. This study demonstrates reduced TAPSE has poor prognosis 
in patients with CHF. It also demonstrates COPD as being possible confounder right 
heart pathology.  
 Caso et al.16 explored the influence of COPD on TAPSE in a prospective study of 
63 patients. TAPSE was reduced in only patients with COPD and pulmonary 
hypertension, with mean measurements of 14.0 + 5.9 but was within physiological 
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normal limits of 19 + 3.9 in COPD patients without pulmonary hypertension. As PE can 
raise pulmonary arterial pressure, this demonstrates possible confounding by COPD in 
PE patients.  
 The existing literature has associated COPD and CHF with reduced TAPSE. 
These findings have also correlated with an increased mortality in patients with reduced 
TAPSE. CHF and COPD may confound results as to the pathophysiology behind the 
reduction in TAPSE, as well with the cause for increased mortality. In previous studies 
CHF and COPD patients have been included in study populations, but we will exclude 
patients with history of these pathologies from our study to limit confounding. 
 
2.3.2 Risk factors for hemodynamic decompensation in pulmonary embolism  
 There are other risk factors, such as advanced age, malignancy and concomitant 
disease, which put individuals at risk for adverse events when diagnosed with PE. These 
factors may be independently associated with mortality or contributory to PE pathology 
in causing mortality. In order to adequately assess the prognostic power of TAPSE, the 
following risk factors should be controlled for as they have been identified as 
contributing to increased mortality and escalation of care in PE patients.   
 
Age 
 In normotensive patients presenting with acute PE, increased age has been 
associated with increased mortality. In analysis of clinical outcomes from the 
International Cooperative Pulmonary Embolism Registry (ICOPER) Goldhaber et al.4 
found an association between age >70 and 3-month mortality with a hazard ratio of 1.6. 
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This study did not prescribe any treatment algorithms or management guidelines for 
patients however, and the international design of the study allows for a wide degree of 
treatments, possibly confounding results.  
 Lopez-Jiminez et al.33 found an odds ratio of 3.6 between age  >80 and mortality, 
with 3.7% mortality of the 2890 patients with age >80 registered in the Registro 
Informatizado de la Enfermedad TromboEmbólica (RIETE). This study assesses PE 
patients in a Spanish registry making it not entirely applicable to US populations, but the 
findings are consistent with other studies.  
 Age is a variable in the PESI and sPESI prognostication models for acute PE. 
This variable was derived based on the association between age >65 and 30-day mortality 
in 10,354 PE patients discharged from 186 Pennsylvania hospitals between 2000 and 
2002 34,35. This study found a beta coefficient of 0.03 associated with each year of patient 
age associated with 30-day mortality. Age >65 was independently associated with 
mortality in this study, and have been further validated in follow up literature36,37.  
 Age >80 was associated with increased mortality in normotensive patients with 
acute PE in the study by Grifoni et al.5, though it was not associated with in hospital 
mortality in the cohort studied by Ribeiro et al.2,5. Overall the literature suggests an 
association between increased age and mortality in acute pulmonary embolism patients. 
This has influenced our study as we have set our inclusion criteria to patients <75 years 
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Malignancy 
 Malignancy has been associated with increased mortality in patients presenting 
with acute pulmonary embolism. Goldhaber et al.4 found cancer to have a hazard ratio of 
2.3 when assessing 2454 patients in the ICOPER registry. As with age, the validity of this 
study is hurt by its lack of management guidelines in patients. The large population size 
however benefits this study and the findings are in line with other studies.  
 A 2018 retrospective cohort of 8641 patients by Alotaibi et al.38 found cancer to 
predict mortality in all age groups. The strongest association between cancer and < 3 
month mortality was found in women and men <50 years old with hazard ratios of 17.85 
and 2.323 respectively. This was a large study, but did have some limitations in that its 
retrospective nature limited researchers ability to identify cause of death, and there was 
no standard treatment prescribed. 
 
Concomitant Disease  
 Other diseases occurring with pulmonary embolism have been associated with 
adverse outcomes. Goldhaber et al.4 identified CHF and COPD as being associated with 
increased mortality in patients with PE with hazard ratios of 2.4 and 1.8 respectively. 
CHF and COPD are pathologies, which have not been excluded from other studies. The 
presence of CHF and COPD may influence TAPSE, as well as prognosis of PE. 
 COPD and CHF are variables present in the PESI and sPESI scores. These 
diseases were associated with worse prognosis in PE patients in a study by Aujesky et 
al.36. The derivation sample of the PESI score consisted of 10,354 PE patients found a 
beta coefficients of 0.31 and 0.30 associating CHF and chronic lung disease respectively 
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with 30-day mortality. Through use of this measure in the PESI and simplified PESI 
scores, the association between chronic lung disease and COPD have been further 
validated in the literature37.  
 
2.4 Review of Relevant Methodology 
2.4.1 Primary outcomes 
 Studies have correlated reduced TAPSE with poor prognosis in pulmonary 
embolism. These studies have previously used set values of TAPSE indicating right 
ventricular dysfunction. Other studies have assessed TAPSE on a continuous scale, 
demonstrating the mean TAPSE at which adverse events occur. Our study follows the 
format of the latter as it allows a clear differentiation between dysfunction defined by 
TAPSE and normal function. TAPSE definition of dysfunction most commonly varies 
between 14mm and 17mm in the literature. Our study chose a TAPSE value of 15mm to 
define RVD, as it has more clear association with mortality in the study by Pruszycyk et 
al. 17 and allows for a more clearly established difference from physiologically normal 
TAPSE.  
 The literature traditionally identified the outcomes of interest as being mortality 
and escalation of care. Evaluation of mortality can vary in range. Studies have established 
a 3-month mortality tend to see a greater mortality, however this is not always due to 
increase PE mortality. The majority of PE related death comes during hospitalization 
however4,39. For this reason and to reduce confounding with mortality from other causes 
we have limited our study of mortality to during hospitalization. 
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 Care for normotensive patients presenting with acute PE begins with heparin 
therapy. The use of thrombolytic therapy in submassive PE patients has been contentious. 
Sharifi et al.40 found no statistically significant outcome in total mortality in using 
thrombolysis on submassive patients, though it did reduce mean length of stay from 4.9+ 
0.8 days to 2.2 + 0.5 days in the group receiving thrombolysis. Meyer et al.41 found an 
odds ratio of 0.44 of mortality or hemodynamic decompensation when using fibrinolytics 
in moderate risk PE compared to placebo, but also had an odds ratio of 5.55 in major 
extracranial bleeding in the group receiving fibrinolysis. These findings demonstrate 
minimal utility in therapy beyond anticoagulation for hemodynamically stable patients 
with acute PE.  Thrombolytic therapy and embloectomy have been identified as 
beneficial in hemodynamically unstable patients however3. Our study can thus identify an 
endpoint being escalation of therapy beyond heparin, as an outcome if it is indicated 
through hemodynamic decompensation.  
 
2.4.1 Secondary outcomes 
 The majority of patients diagnosed with APE in the ED are admitted to the 
hospital.  Schissler et al.42 found 83% of patients diagnosed with PE were admitted to the 
hospital from emergency departments in a cross sectional study of 283 PE diagnoses 
made in the ED. In a study of 61,249 admissions for pulmonary embolism from 263 
hospitals, Admon et al.43 found an ICU admission rate that ranged from 2.9%- 79.9% for 
PE patients. As low risk pulmonary emboli can be treated as outpatient it becomes 
increasingly important to risk stratify patients presenting with APE and understanding 
how their hospital course goes. Chaudhary et al.11 found a length of stay difference 
 41  
between patients with RVD and those without RVD of 7.13 days and 5.46 days 
respectively. Daley et al.27 found patients admitted with PE had an average length of stay 
of 6.3 + 5.3 days. Cohen et al.44 found an average hospital length of stay of 5.4 days, with 
length of stay being longer in hospitals with greater use of transthoracic echocardiogram 
in prognosis of PE.  Pulmonary embolism has a range of presentation and often involves 
hospitalizations of > 5 days. By looking at how a TAPSE < 15mm influences hospital 
length of stay compared to a TAPSE >17mm, it will allow clinicians to better assess the 
care needs of patients and better plan their stay.  
 
2.5 Conclusion  
 The existing evidence around the use of tricuspid annular plane systolic excursion 
in prognosis of pulmonary embolism demonstrates a clearly established trend in 
suggesting that a reduced TAPSE is associated with increased mortality and need for 
escalation of care. The definition of reduced TAPSE has varies from 10mm to 17mm in 
different studies with threshold values of 15mm and 17mm being the most common17,18. 
Our study has identified 15mm as our definition of abnormal TAPSE as it is most 
strongly associated with mortality in the literature and as it a lower value of TAPSE it is 
included in a larger number of studies17. Though this will reduce the incidence of 
abnormal TAPSE, we believe it will provide a more definite prognosis, given the 
literature reviewed.   
 Studies identifying the reliability of ultrasound in identifying right ventricular 
dysfunction have ranged from kappa values of .45 to .85 in regard to interobserver 
accuracy25,26,29. There is evidence that TAPSE has the greatest interobserver consistency, 
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making it a more ideal echocardiographic marker of right ventricle dysfucntion25,27.  
Point-of-care echocardiography in the emergency department, though not commonly 
explored in the literature has demonstrated reproducible and consistent findings when 
obtained and read by emergency physicians29. The majority of these studies have been 
done on emergency physicians specifically trained in ultrasound. Because the literature 
has not validated FOCUS performed by novice emergency physicians, our study will 
only utilize academic emergency departments with specific ultrasound curricula and 
emergency providers experienced in ultrasound. The use of FOCUS in measuring TAPSE 
will be generalizable as TAPSE measurement demonstrates reliability and point-of-care 
ultrasound is already utilized in the ED to identify RVD. Based on the literature, TAPSE 
measured by FOCUS may provide more reliable and reproducible measure of RVD with 
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CHAPTER THREE: STUDY DESIGN  
3.1 Study Design  
We propose a multi-center, prospective cohort study conducted in emergency 
departments at Yale New Haven Hospital, Boston Medical Center, and Rhode Island 
Hospital assessing outcomes of mortality and need for escalation of care beyond heparin 
alone of two cohorts with either a TAPSE < 15mm or a TAPSE > 17mm as measured by 
point-of-care echocardiography.  
 
3.2 Study Population, Sampling, and Recruitment  
 The study will take place over twenty months, from January 2019 until August 
2020. The study will use convenience sampling to screen all hemodynamically stable 
patients diagnosed with acute pulmonary embolism by computed tomography pulmonary 
angiogram as they present to participating emergency departments. Flyers (Appendix C) 
will be placed in participating ED's requesting that investigators be contacted for patients 
with acute PE on CTPA. Investigators will also monitor hospital electronic ED track 
board for eligible patients fitting inclusion criteria.  Patients will be approached and 
informed consent obtained.  
 Inclusion criteria include age greater than 18 years old and pulmonary embolism 
diagnosed on CTPA. Exclusion criteria includes hemodynamic instability, as defined as a 
systolic arterial blood pressure of < 90mm Hg or a drop of at least 40 mm Hg for at least 
15 min or shock, age >75 years, history of malignancy, and concomitant diagnosis of 
congestive heart failure, chronic obstructive pulmonary disease or pulmonary 
hypertension.  
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3.3 Subject Protection and Confidentiality  
 All hospitals will require approval by their own institutional review boards. We 
will seek approval for our research protocols from the Yale Human Research Committee 
Institutional Review Board. Our study will comply will all applicable criteria of the Yale 
University IRB Policy 100. All investigators will have evidence of institutional training 
in the Health Insurance Portability and Accountability Act of 1996 (HIPPA) Privacy 
Training and complete the National Institute of Health (NIH) Protecting Human Research 
Participant Training via the NIH's training website. All potential conflicts of interest will 
be disclosed to the institutional review board and principle investigator.  
 This observational study will follow chart review protocol. There is no risk to any 
subject in either cohort. This study will not affect treatment plans or prescriptions 
because of this study. Consent will be obtained by all patients participating in the study 
by consent form (Appendix D). Requested information from patients includes MRN, age, 
sex, race, past medical history, current medical problems, and records of past 
hospitalizations.  
 Patient privacy will be maintained throughout the study. Patient names on clinical 
data will be de-identified. Patient information will only be accessed on secure 
institutional servers.  Computers housing patient data will be password protected 
requiring username and password to log in. Investigators will communicate patient 
sensitive data only with email encryption. Any physical copies of patient information will 
be kept in binders in locked file cabinets in locked offices. All members of the 
investigation team will maintain HIPPA compliance throughout the study.  
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3.4 Study Variables and Measures  
 This prospective cohort study will be comparing one group with a TAPSE < 
15mm and another group with a TAPSE > 17mm. TAPSE of < 15mm will be the marker 
of right ventricle dysfunction in the study. Emergency department physicians with 
experience in point-of-care focused cardiac ultrasound will take TAPSE measurement 
within 6 hours of initiation of heparin therapy. A blinded off-site cardiologist will 
evaluate TAPSE measurements.  Measurements will be taken in apical 4-chamber view 
in m mode during echocardiography. Other measurements associated with RV dilation 
will be taken. These will include right ventricular diameter, right ventricular end diastolic 
diameter to left ventricular end diastolic ratio, and RV hypokinesia.  
 The primary outcomes of interest are in-hospital mortality and need for escalation 
of care beyond heparin alone. Escalation of care beyond heparin alone is defined as the 
use of thrombolytic therapy, embolectomy, endotracheal intubation, or the use of 
vasopressors. These are markers of poor disease outcome and treatment failure of 
anticoagulation therapy alone. The primary outcomes are both dichotomous variables. 
The outcomes will be evaluated through the entire hospitalization of up to 14 days.  
 Our investigators are also comparing secondary outcomes of hospital length of 
stay between groups. This is a continuous variable, which is defined as days spent in 
hospital. The other secondary outcome is mortality of patients with a RV/LV end 
diastolic diameter of >1. This is a dichotomous outcome.  
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3.5 Confounding Factors  
  We will collect baseline data of possible confounding variables, which may 
influence patient outcomes. These characteristics include age, sex, BMI, blood pressure, 
heart rate, oxygen level, cigarette use, and history of coagulopathy, hypertension, or 
coronary artery disease. We will also record data on the presence of dyspnea, chest pain, 
syncope, cough, hemoptysis, palpitation, or concomitant DVT. These confounding 
factors are shown in table 1.  
 
3.6 Data Collection  
 Measurement of TAPSE will be performed by emergency department physicians 
who are experienced in point-of-care focused cardiac ultrasound using a Phillips Sparq 
Ultrasound System. All investigators will be credentialed in FOCUS or complete a 1 day 
workshop on FOCUS. FOCUS will be performed within 6 hours of initiation of heparin 
therapy. After initial ultrasound, data will be performed through chart review of the 
participants. Investigators performing chart review will be blinded to which TAPSE 
group the patient belongs. Data will be collected and arranged in Excel files for statistical 
analysis by the sub-investigator.  
 
3.7 Sample Size Calculation  
 The primary outcomes of this study are in-hospital mortality and need for 
escalation of care beyond heparin alone. Both outcomes are dichotomous which will be 
presented as incidence proportions. We will be comparing two cohorts with a sample size 
ratio of 5:1 using a one tailed rest with power of 80% and confidence interval of 95% for 
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the primary endpoint. We require an estimate sample size of 42 for the TAPSE < 15mm 
group and 206 for the TAPSE >17mm group. Sample data was acquired from Lobo et. 
al.1 and Paczynska et al.2, comparing incidence of reduced TAPSE in acute pulmonary 
embolism patients. The sample size calculation is in Appendix E and was performed at 
http://www.openepi.com/SampleSize/SSCohort.htm. 
 
3.8 Analysis  
 All data will be analyzed using Statistical Analysis System Software. To compare 
the incidence proportions of mortality and escalation of care beyond heparin alone 
between the TAPSE < 15mm and TAPSE > 17mm groups we will use a chi square test 
with alpha of 0.05. Secondary outcome of hospital length of stay will be evaluated using 
multiple linear regression. RV/LV end diastolic diameter >1 mortality incidence 
proportion will be assessed using a chi square test. Incidence proportions of mortality in 
TAPSE < 15mm and RV/LV end diastolic diameter >1 will be compared using a 
conditional exact test.  
 Baseline data for study populations will be analyzed and adjusted to control for 
confounding. Nominal variables such as age and presence of symptoms and medical 
history will be compared using chi-squared tests. Continuous variables such as systolic 
blood pressure and BMI will be compared using unpaired t-tests. Multiple linear 
regression will be used to adjust for confounding variables in primary and secondary 
outcomes.  
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3.9 Timeline and Resources  
 The total length of the study including recruitment, patient follow up, and data 
analysis will be 24 months. Recruitment will begin on January 2, 2019 and continue 
through August 2, 2020. Data analysis will be completed by December 2020. The 
primary investigator (PI) will be Christopher Moore, MD, and the co-primary 
investigator will be Matthew Drause, PA-SII, who will centrally handle the data analysis 
and statistics. Numerous staff will be required at Yale New Haven Hospital, Rhode Island 
Hospital and Boston Medical Center to identify participants in the ED, discuss the study 
and obtained informed consent. Following patient enrollment, emergency department 
staff will also make sure all baseline data is present in the electronic medical record 
(EMR). Emergency physicians trained and experienced in FOCUS will be asked to 
participate in the study, who will be responsible for performing and reading the 
echocardiogram in consented patients. 
  Participating hospitals were selected because they are high volume emergency 
departments with established emergency ultrasound fellowship programs. All 
participating hospitals use EPIC EMR, allowing for consistent data reference and 
collection. A computer programmer will design algorithms required to gather patient 
data.  Sufficient office space and access to secured computers will be required at each 
site. Data analysis will take place in offices at Yale New Haven Hospital.  
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Table 1. Baseline Patient Characteristics 
  
Characteristics   TAPSE < 
15mm Group 
TAPSE > 
17mm Group  
p value  
Age Mean (SD)   unpaired t-
test  
 <50 (%) (%) chi-squared  
 50-65  (%) (%) chi-squared 
 65-75 (%) (%) chi-squared 
Sex Male (%) (%) chi-squared 
 Female (%) (%) chi-squared 




Mean (SD)   unpaired t-
test 
Heart Rate  >100 (%) (%) chi-squared 
Pulse 
oxygenation  
<90% (%) (%) chi-squared 
Symptomology  Chest Pain (%) (%) chi-squared 
 Palpitation (%) (%) chi-squared 
 Cough (%) (%) chi-squared 
 Dypsnea (%) (%) chi-squared 
 Hemoptysis  (%) (%) chi-squared 
 Syncope (%) (%) chi-squared 
 Concomitant DVT  (%) (%) chi-squared 
Medical 
History 
Hypertension (%) (%) chi-squared 
 Coronary Artery 
Disease  
(%) (%) chi-squared 
 Coagulopathy  (%) (%) chi-squared 
Social History  Cigarette Use (%) (%) chi-squared 
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CHAPTER FOUR: CONCLUSION 
4.1 Advantages and Disadvantages   
 There are several strengths to the proposed study. When compared to the existing 
literature our study will provide a generalizable and utilizable association between 
TAPSE measured by FOCUS in the ED and APE mortality and need for escalation of 
care beyond heparin alone. It will be the first study to use TAPSE measured by FOCUS 
in emergency departments to assess these clinical outcomes in hemodynamically stable 
patients with APE. All echocardiography will be performed by specifically trained 
emergency department physicians, which will reduce the interobserver variability of the 
measurements. ED physicians have been shown to have consistent measurement of 
TAPSE in previous studies1,2. As FOCUS is being increasingly utilized in emergency 
departments3, this study will provide direct insight into its use in measurement of 
TAPSE, and its utility in prognosticating patients with acute PE. Our study population 
will be exclude patients with age > 75 years, active malignancy, CHF, and COPD, which 
have been shown to independently be associated with increased mortality in APE patients 
and independently influence TAPSE. Our study population will be large, and as this is a 
multi-centered study, the results will be more generalizable to a larger population.  
 There will also be a few limitations to our study. The study will be carried out in 3 
different hospitals, which though the hospitals follow the same treatment algorithm for 
APE, may affect consistency if care and introduce some confounding. Because 3 different 
emergency departments will be measuring TAPSE, this also requires a greater number of 
investigators performing FOCUS, which may introduce greater variability in 
measurement. This will be controlled in part by blinded cardiologists confirming TAPSE 
measurements. This study requires identification and enrollment of patients with 
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confirmed PE by ED staff, which may allow for selection bias towards patients with more 
severe presentation, affecting generalizability. The exclusion of patients with age > 75 
years, active malignancy, CHF, and COPD will allow for a more reliable association 
between TAPSE and mortality, however this population makes up a large percent of PE 
patients making results less generalizable. Lastly, we chose the time period for mortality 
and need for escalation of care beyond heparin alone to be only the time in which a 
patient is hospitalized, which, though the most clinically relevant and frequent, may not 
be long enough to have captured all adverse events clinicians would deem disease 
relevant.  
 
4.2 Clinical Significance 
 Acute pulmonary embolism is a disease with high incidence and high mortality. 
As outlined in Chapter 1, the first treatment for hemodynamically stable patients 
presenting with RVD is currently anticoagulation, which continues to carry an inpatient 
mortality rate of 5-10%4,5. As escalation of care is considered it is important to have 
accurate measurements to guide prognosis. Point-of-care focused cardiac ultrasound is 
currently utilized in the ED to assist with diagnosis and prognosis of APE3. Reduced 
TAPSE has been shown to have a strong association with mortality and escalation of care 
in this population. This study will use FOCUS to demonstrate an association between a 
TAPSE < 15mm and mortality and escalation of care beyond heparin alone, in a way that 
is utilizable in emergency departments. This association will allow for clinicians to better 
use an existing technology to obtain a reliable and reproducible measurement of RV 
function to better risk stratify patients and guide their care.   
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Appendix A: Pulmonary Embolism Assessment Tools  
 
Wells Score Revised Geneva Score 
 
Variable 
Previous DVT or PE  
Recent Surgery or immobilization  
Cancer  
Hemoptysis  
Heart rate > 100 beats per minute  
Clinical Signs of DVT 













Age > 65 years old  
Previous DVT or PE 
Surgery or Fracture within 1- month  
Active Malignancy  
Unilateral lower limb pain  
Hemoptysis  
Heart rate 75- 04 beats per minute  
Heart rate > 95 beats per minute  
Pain on lower limb deep palpation and 













Clinical Probability (3 Levels)  
Low - 0-1 points  
Intermediate - 2-6 points  
High - > 7 points  
 
Clinical Probability (2 Levels)  
PE unlikely - 0-4 points 
PE likely - > 4 points  
Clinical Probability (3 Levels)  
Low - 0-3 points  
Intermediate - 4-10 points  
High - > 11 points  
 
Clinical Probability (2 Levels)  
PE unlikely - 0-3 points  
PE likely - >3 points  
 
 
Pulmonary Embolism Rule Out Criteria (PERC Rule) 
-Age < 50 years old 
-Heart rate < 100 beats per minute 
-Oxyhemoglobin saturation >95%  
- No hemoptysis  
- No exogenous estrogen use 
- No prior DVT or PE 
- No unilateral leg swelling  
- No Recent Surgery or Trauma  
PERC > 1- Cannot rule out pulmonary embolism  
 
 
Pulmonary Embolism Severity Index 
(PESI) 





History of Cancer 
History of Heart Failure 
History of Chronic Lung Disease 
Pulse > 110 beats/min  
Systolic blood pressure <100 mm Hg 
Respiratory Rate > 30 breaths/min  
Temperature <36°C 
Altered Mental Status  
Arterial oxyhemoglobin saturation level 
<90% 
Age in years  
+ 10 











Age > 80 years old  
History of Cancer  
History of Heart Failure or  
Chronic lung Disease  
Pulse > 110 beats/min  
Systolic blood pressure <100 mm Hg 










Class I - < 66 points 
Class II - 66 -85 points 
Class III - 86-105 points  
Class IV - 106- 125 points  
0- Low risk 
> 1- High Risk  
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Class V - >125 points  
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Appendix C: Recruitment Flyer 
 
FOR YOUR INFORMATION 
 
This hospital is currently participating in a trial examining the 
prognosis of hemodynamically stable patients with pulmonary 
embolism. Investigators will be assessing the outcomes of patients 
diagnosed with pulmonary embolism on computed tomography 
pulmonary angiogram based upon their tricuspid annular plane 
systolic excursion measurement on point-of-care focused cardiac 




*Please contact study investigators at pager number (248) 495 6294 if you 
are treating a patient meeting the following characteristics.* 
 
 
- New diagnosis of pulmonary embolism on computed tomography 
pulmonary angiogram 
 
- Systolic Blood Pressure >90 mm Hg 
 
- Heparin therapy initiated for less than 5 hours  
 
- Age <75 years  
 
- No known medical history of active malignancy, congestive heart failure, 
chronic obstructive pulmonary disease or pulmonary hypertension. 
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Appendix D: Informed Consent Form   
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR. 1 (2016-2) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN 
HOSPITAL, BOSTON MEDICAL CENTER, RHODE ISLAND HOSPITAL. 
 
Study Title: Prognostic utility of point-of-care ultrasound of tricuspid annular plane 
systolic excursion in pulmonary embolism patients in the emergency department  
Principal Investigator: Dr. Christopher Moore, MD: Matthew Drause, PA-SII  
Funding Source: YCCI 
 
Invitation to Participate and Description of Project 
You are invited to participate in a research study designed to look at the effect a reduced 
tricuspid annular plane systolic excursion has on the outcomes of hemodynamically 
stable patients with acute pulmonary embolism. You have been asked to participate 
because you have been diagnosed with an acute pulmonary embolism, have a systolic 
blood pressure greater than 90 mmHg, are younger than 75, with no active malignancy or 
history of congestive heart failure or chronic obstructive pulmonary disease.  This study 
aims to enroll approximately 214 individuals at 3 emergency departments to determine if 
a tricuspid annular plane systolic excursion of < 15mm influences mortality or need for 
escalation of care beyond heparin alone.  
 
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision.  This consent 
form gives you detailed information about the research study, which a member of the 
research team will discuss with you.  This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures 
and possible benefits. Once you understand the study, you will be asked if you wish to 
participate; if so, you will be asked to sign this form.  
 
Description of Procedures 
 
➢ You will be given a bedside transthoracic echocardiogram by an emergency 
department physician, which will measure the size or your right ventricle, the 
movement of your right ventricle and the movement of your tricuspid valve.  
➢ An echocardiogram is an image of your heart. It is taken over your skin and has 
no exposure to radiation or toxins.  
➢ Transthoracic echocardiograms are routinely taken in the emergency department 
but are not always taken for every patient with a pulmonary embolism. You will 
be given a bedside echocardiogram to measure your right ventricle.  
➢ Based on the measurement of the movement of the tricuspid valve of your right 
ventricle you will be put into either the TAPSE < 15mm or TAPSE >17mm 
groups.  
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➢ You will receive IV heparin for medical management of your pulmonary 
embolism initially, as is the standard treatment in the emergency department, but 
all further medical decisions will be made by your internal medicine team while 
in the hospital.  
➢ Your medical records will be reviewed by your research clinician for the 
following information: medical history, medicines administered while in the 
hospital, vital signs while in the hospital, bedside echocardiogram images and 
reading, notes regarding rapid response events, and clinical team notes while 
admitted.    
 
If you agree to participate in this study, you will be asked to receive a bedside transthoracic 
echocardiogram that will measure the function of the right side of your heart, the movement of your 
tricuspid valve, and the size of your right ventricle. You will also grant us access to your electronic 
medical record to monitor your hospital course. This study will not effect your treatment.  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time. 
 
You will be told of any significant new findings that are developed during the course of your 
participation in this study that may affect your willingness to continue to participate. 
 
Risks and Inconveniences 
 
➢ There is no risk associated with echocardiogram. Incidental findings outside of the scope 




➢ There will be no direct benefit for your participation in this study. We hope that the 
information obtained in this study will increase our understanding of how tricuspid annular 
plane systolic excursion measured in the emergency department with point-of-care 
echocardiogram is associated with mortality and escalation of care, and id it may be 








Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or State law.  
Examples of information that we are legally required to disclose include abuse of a child or 
elderly person, or certain reportable diseases. All patient information will be de-identified by 
removing, name, date of birth and MRN. Patient information will be kept on a secure server 
access only password-protected computers. All physical copies of patient data will be kept in 
locked cabinet in a locked office.   When the results of the research are published or discussed in 
conferences, no information will be included that would reveal your identity unless your specific 
consent for this activity is obtained.   
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Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on human 
subjects) may inspect study records during internal auditing procedures.  However, these 
individuals are required to keep all information confidential.  
 
In Case of Injury 
 
If you are injured while on study, seek treatment and contact the study doctor as soon as you are 
able.   
 
Yale School of Medicine Yale-New Haven Hospital, Boston Medical Center, Rhode Island 
Hospital do not provide funds for the treatment of research-related injury.  If you are injured as a 
result of your participation in this study, treatment will be provided.  You or your insurance carrier 
will be expected to pay the costs of this treatment.  No additional financial compensation for injury 
or lost wages is available. 
 
You do not give up any of your legal rights by signing this form. 
 
Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary. You are free to choose not to take part in this study.   
Refusing to participate will involve no penalty or loss of benefits to which you are otherwise 
entitled (such as your health care outside the study, the payment for your health care, and your 
health care benefits).  However, you will not be able to enroll in this research study and will not 
receive study procedures as a study participant if you do not allow use of your information as part 
of this study. 
 
Withdrawing From the Study 
 
If you do become a subject, you are free to stop and withdraw from this study at any time during 
its course.  
 
To withdraw from the study, you can call a member of the research team at any time and tell them 
that you no longer want to take part.   
 
The researchers may withdraw you from participating in the research if necessary.   
 
 Withdrawing from the study will involve no penalty or loss of benefits to which you are otherwise 
entitled.  It will not harm your relationship with your own doctors or with Yale-New Haven 
Hospital, Boston Medical Center, or Rhode Island Hospital.   
 
When you withdraw from the study, no new health information identifying you will be gathered 
after that date.  Information that has already been gathered may still be used and given to others 
until the end of the research study, as necessary to insure the integrity of the study and/or study 
oversight.   
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Questions 
 
We have used some technical terms in this form.  Please feel free to ask about anything 
you don't understand and to consider this research and the consent form carefully – as long as you 




I have read (or someone has read to me) this form and have decided to participate in the project 
described above.  Its general purposes, the particulars of my involvement and possible hazards and 
inconveniences have been explained to my satisfaction.  My signature also indicates that I have 




      










Signature of Principal Investigator  Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
If you have further questions about this project or if you have a research-related problem, you 
may contact the Principal Investigator Matthew Drause 248-495-6294. 
If, after you have signed this form you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other 
than the researchers to discuss problems, concerns, and questions you may have concerning this 
research, or to discuss your rights as a research subject, you may contact the Yale Human 
Investigation Committee at (203) 785-4688.  
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Appendix E: Sample Size Calculation   
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